PainResearch Phase

Endomorphin-1

Endogenous peptide

Overview

Endomorphin-1 is a tetrapeptide (Tyr-Pro-Trp-Phe) that exhibits highly selective agonist activity at the mu-opioid receptor, the primary target for analgesic opioids. It is one of two endomorphin isoforms and represents the most selective endogenous mu-opioid ligand identified to date.

Mechanism of Action

Endomorphin-1 is distributed in pain-processing regions of the central nervous system. Its selective mu receptor activity theoretically offers potent analgesia with a potentially different side effect profile compared to less selective opioids..

Research Summary & Key Findings

Preclinical studies have shown that endomorphin-1 produces potent analgesia in rodent models when administered intrathecally or intracerebroventricularly. Challenges including poor metabolic stability, limited blood-brain barrier penetration, and rapid enzymatic degradation have prevented clinical development. Research efforts have focused on designing stabilized analogs and prodrug strategies to improve pharmacokinetic properties.

Clinical Status

Research Phase

Endomorphin-1 is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Endogenous peptide

Related Peptides in Pain

Find a Provider

Find a verified provider who offers Endomorphin-1 therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Endomorphin-1.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.